Article
Development and validation of a novel prognostic index for mantle cell lymphoma integrating TP53 mutations (MIPI53).
British journal of haematology - 1 Jun 2026
Bastos-Boente Miguel, Medina-Herrera Alejandro, Navarro-Bailón Almudena, Ferrero Simone, Sarasquete María Eugenia, Jiménez Cristina, García-Álvarez María, Antón Alicia, Balanzategui Ana, Moia Ricardo, Re Alessandro, Boccomini Carola, Balzarotti Monica, Zilioli Vittorio Ruggero, da Silva Maria Gomes, Díaz-Gálvez Francisco Javier, González-Mena Beatriz, Peñarrubia María Jesús, Fernández-Ferrero Silvia, de Ramón Cristina, Blanco Óscar, Cabero Almudena, Ladetto Marco, García-Sanz Ramón, Gutiérrez Norma C, Martín García-Sancho Alejandro, Alcoceba Miguel
Abstract excerpt
Mantle cell lymphoma (MCL) is a clinically heterogeneous disease with varying treatment responses and outcomes. Despite the utility of the Mantle Cell Lymphoma International Prognostic Index (MIPI), its predictive capacity can be enhanced by integrating genetic markers such as TP53 mutations. We analysed 143 newly diagnosed MCL patients from a real-world cohort, assessing TP53 mutational status, clinical and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.